|4Mar 16, 5:04 PM ET

Arix Bioscience Holdings Ltd 4

4 · IMARA Inc. · Filed Mar 16, 2020

Insider Transaction Report

Form 4
Period: 2020-03-16
Transactions
  • Purchase

    Common Stock

    2020-03-16$16.00/sh+187,500$3,000,0001,554,558 total(indirect: By entities affiliated with Arix Bioscience plc)
  • Conversion

    Common Stock

    2020-03-16+1,367,0581,367,058 total(indirect: By entities affiliated with Arix Bioscience plc)
  • Conversion

    Series B Preferred Stock

    2020-03-168,611,1100 total(indirect: By entities affiliated with Arix Bioscience plc)
    Common Stock (1,367,058 underlying)
Footnotes (2)
  • [F1]On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  • [F2]These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION